Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2006-11-07
2006-11-07
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S139100, C424S141100, C424S143100, C424S144100, C424S152100, C424S153100, C424S154100, C424S172100, C424S173100, C424S184100, C424S185100, C530S387100, C530S387900, C530S388100, C530S388200, C530S388220, C530S388700, C530S388730, C530S388750, C530S350000
Reexamination Certificate
active
07132099
ABSTRACT:
A polypeptide (8F4 molecule) with a T-cell costimulating biological activity is disclosed, as well as monoclonal antibodies against said 8F4 molecule and hybridoma cells which produce the monoclonal antibodies, the use as medicaments of substances which inhibit the biological activity of the disclosed 8F4 polypeptide, in particular monoclonal antibodies, natural or synthetic ligands, agonists or antagonists, in particular for preventing or treating diseases which involve the immune system, the use of said 8F4 molecule or cells containing said 8F4 molecule as medicaments, in particular for preventing or treating diseases which involve the immune system, and the use of substances which specifically recognize the disclosed polypeptide, in particular monoclonal antibodies, natural or synthetic ligands, agonists or antagonists, for diagnosing diseases which involve the immune system.
REFERENCES:
patent: WO 89/10398 (1989-11-01), None
patent: WO 90/04180 (1990-04-01), None
patent: WO 98/38216 (1998-09-01), None
patent: WO 99/15553 (1999-04-01), None
Ozkaynak et al. Nature Immunol. Jul. 2001; 2(7):591-596.
Gonzalo et al. Nature Immunol. Jul. 2001; 2(7):597-604.
Wills-Karp M., Immunopharmacol. 2000; 48:263-268.
Keane-Myers et al, J. Immunol. Jan. 15, 1998 ; 160 :1036-1043.
Mathur et al., Am. J. Respir. Cell Mol. Biol. 1999; 21:498-509.
Barbey et al., 1990, “DEL cell line: a “malignant histiocytosis” CD30+ t(5;6)(q35;p21) cell line.” Int J Cancer. 45(3):546-53.
Buonfiglio et al., 1999, “Characterization of a novel human surface molecule selectively expressed by mature thymocytes, activated T cells and subsets of T cell lymphomas”, Eur. J, Immunol. 30:3463-3467.
Buonfiglio et al., 2000, “The T cell activation molecule H4 and the CD28-like molecule ICOS are identical”, Eur. J, Immunol. 30:3463-3467.
Chambers and Allison, 1997, “Co-stimulation in T cell responses.” Curr Opin Immunol. 9(3):396-404. Review.
Chirgwin et al., 1979, “Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.” Biochemistry. 18(24):5294-9.
Fischer et al., 1988, “A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin's lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor beta-chain gene.” Blood. 72(1):234-40.
Freeman et al., 1993, “Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation.” Science. 262(5135):909-11.
Greenfield et al., 1998, “CD28/B7 costimulation: a review”. Crit. Rev. Immunol. 18:389-418.
Groettrup et al., 1996, “A third interferon-gamma-induced subunit exchange in the 20S proteasome.” Eur J Immunol. 26(4):863-9.
Hara et al., 1985, Human T cell activation. II. A new activation pathway used by a major T cell population via a disulfide-bonded dimer of a 44 kilodalton polypeptide (9.3 antigen). J Exp Med. 161(6):1513-24.
Kirk et al., 1997, CTLA4-lg and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A. 94(16):8789-94.
Kohler and Milstein, 1975, “Continuous cultures of fused cells secreting antibody of predefined specificity.” Nature. 256(5517):495-7.
Kroczek RA., 1993, “Southern and northern analysis.” J Chromatogr. 618(1-2):133-45. Review.
Lanier et al., 1995, “CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL.” J Immunol. 154(1):97-105.
Lenschow et al., 1996, “CD28/B7 system of T cell costimulation”, Annu. Rev. Immunol. 14:233-258.
Linsley et al., 1992, “Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes.” J Exp Med. 176(6):1595-604.
Lucas et al., 1995, “Naive CD28-deficient T cells can initiate but not sustain an in vitro antigen-specific immune response.” J Immunol. 154(11):5757-68.
Nishioka et al., 1994, “The role of CD40-CD40 ligand interaction in human T cell-B cell collaboration.” J Immunol. 153(3):1027-36.
Redoglia et al. 1996, “Characterization of H4: a mouse T lymphocyte activation molecule functionally associated with the CD3/T cell receptor”, Eur. J. Immunol. 26:2781-2789.
Riley et al., 1997, “Intrinsic resistance to T cell infection with HIV type 1 induced by CD28 costimulation.” J Immunol. 158(11):5545-53.
Schneider et al., 1982, A one-step purification of membrane proteins using a high efficiency immunomatrix. J Biol Chem. 257(18):10766-9.
Shahinian et al., 1993, “Differential T cell costimulatory requirements in CD28-deficient mice.” Science. 261(5121):609-12.
Vogeli and Kaytes, 1987, “Amplification, storage, and replication of libraries.” Methods Enzymol.152:407-15.
Wallace and Miyada, 1987, “Oligonucleotide probes for the screening of recombinant DNA libraries.” Methods Enzymol.152:432-42.
Westermeier, 1997, “A Guide to Methods and Applications of DNA and Protein Separations.”Electrophoresis in Practice, VCH Verlagsgesellschaft, Weinheim.
Wozney, 1990, “Using purified protein to clone its gene.” Methods Enzymol. 182:738-51.
Bundersrepublik Deutschland
Gambel Phillip
Ouspenski Ilia
LandOfFree
Methods of modulating T lymphocyte costimulation with an... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of modulating T lymphocyte costimulation with an..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of modulating T lymphocyte costimulation with an... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3694395